F-star Therapeutics

F-star Therapeutics is a UK-based biotech focused on creating next-generation bispecific antibodies for immuno-oncology. Its core achievement is the development of the proprietary Fcab and mAb2 platforms, which generate tetravalent, IgG-like bispecific antibodies designed for enhanced stability, manufacturability, and biological activity. The company's strategy involves advancing its internal pipeline of clinical and preclinical assets while securing strategic partnerships to validate and expand the utility of its modular technology. Following its NASDAQ IPO in 2020, F-star has progressed key assets into clinical trials, positioning itself in the competitive bispecific antibody landscape.

Proprietary Fcab and mAb2 platforms enabling the creation of tetravalent, bispecific antibodies with a native IgG structure, designed for enhanced stability, pharmacokinetics, and manufacturability.

F-star competes in the crowded bispecific antibody field against large pharma (Roche, Amgen, J&J) and biotech platforms (Genmab, Zymeworks). Its key differentiation is the tetravalent, native IgG structure of its mAb2 molecules, which aims to offer superior drug-like properties over fragment-based or asymmetrically engineered formats.